Finance News World

(Albany, US) On November 04, 2026, DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the GERD market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.

Discover the latest drugs and treatment options in the GERD Market @ https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Key Takeaways from the Gastroesophageal Reflux Disease Report

• In August 2026, Implantica received FDA PMA approval for RefluxStop, an implantable device that treats GERD by restoring normal anatomy without constricting the lower esophageal sphincter, opening its entry into the US market.

• In May 2026, Phathom Pharmaceuticals presented new Phase III pHalcon-NERD-301 data for vonoprazan at DDW 2026, and Braintree Laboratories presented positive Phase III TRIUMpH-EE results for tegoprazan.

• In January 2026, Braintree submitted an NDA to the FDA for tegoprazan (BLI5100) in adults with GERD, with approval anticipated in January 2027.

• Phathom reported about USD 58 million in VOQUEZNA revenue in Q1 2026 and surpassed 1 million vonoprazan prescriptions dispensed in the US by Q4 2025.

• The US GERD market was about USD 3,400 million in 2025 and is projected to reach about USD 6,500 million by 2036, a CAGR of about 6.3% from 2026 to 2036.

• DelveInsight estimates about 33.7 million diagnosed prevalent GERD cases in the US in 2025, with females accounting for about 60%.

• DelveInsight’s report depicts a space moving beyond proton pump inhibitors (PPIs) toward potassium-competitive acid blockers (P-CABs) and microbiome-based therapies.

• Leading GERD companies include Phathom Pharmaceuticals, Takeda Pharmaceutical, Braintree Laboratories, Sebela Pharmaceuticals, ISOThrive, and others.

• Promising therapies include vonoprazan (VOQUEZNA), tegoprazan (BLI5100), ISOT-101, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastroesophageal Reflux Disease Treatment Drugs

Gastroesophageal Reflux Disease Overview

GERD is a chronic digestive disorder in which stomach contents reflux into the esophagus, causing troublesome symptoms or complications, mainly from dysfunction of the lower esophageal sphincter. Non-erosive GERD is the largest subcategory, and nighttime symptoms affect an estimated 80% of patients. Untreated disease can lead to erosive esophagitis, strictures, Barrett’s esophagus, and esophageal adenocarcinoma. Diagnosis rests on symptoms and an empirical acid-suppression trial, with endoscopy, pH monitoring, impedance-pH testing (the gold standard), and manometry used in persistent or atypical cases. Management combines lifestyle changes with PPIs such as omeprazole and esomeprazole as standard of care, H2 blockers in milder disease, and P-CABs such as vonoprazan as newer options.

Common symptoms include:

• Heartburn and acid regurgitation

• Chest discomfort

• Difficulty swallowing (dysphagia)

• Chronic cough and hoarseness

• Sleep disturbances

Gastroesophageal Reflux Disease Emerging Drugs Profile

Tegoprazan (BLI5100): Braintree Laboratories (Sebela Pharmaceuticals) Tegoprazan is a novel oral P-CAB for acid-related gastrointestinal disease that has completed its Phase III TRIUMpH program in GERD, including 24-week maintenance data. An NDA was submitted in January 2026, and it is already approved in 21 countries. Currently, the drug is in Phase III, with an NDA submitted.

ISOT-101: ISOThrive ISOT-101 is an oral, microbiome-based therapy built on a proprietary digestion-resistant prebiotic carbohydrate (maltosyl-isomalto-oligosaccharides, MIMO). It modulates the gastrointestinal and esophageal microbiome rather than suppressing acid, and targets patients with persistent symptoms despite PPIs. Currently, the drug is in Phase II.

Explore groundbreaking therapies and clinical trials in the GERD Pipeline @ Gastroesophageal Reflux Disease Treatment Drugs

Gastroesophageal Reflux Disease Market Drivers

• Rising prevalence: Obesity, sedentary lifestyles, unhealthy diets, and aging populations are expanding the treatable patient pool.

• Adoption of P-CABs: Vonoprazan and emerging agents offer faster, more potent, and more sustained acid suppression than PPIs, with strong US uptake.

• PPI-refractory unmet need: A substantial share of patients, especially those with non-erosive disease, still have symptoms on standard therapy.

• Late-stage pipeline: Tegoprazan has an NDA under review, with approval anticipated in January 2027.

• Novel mechanisms: Microbiome-based therapy such as ISOT-101 addresses causes beyond acid production.

• Device innovation: RefluxStop’s US approval adds a non-drug option for chronic reflux.

• Exclusivity and access: Vonoprazan’s NCE exclusivity through 2032 and patient savings programs support commercial performance.

Gastroesophageal Reflux Disease Market Barriers

• Entrenched, low-cost PPIs: PPIs are standard of care and widely available as generics, setting a low price benchmark.

• Competition within the P-CAB class: Tegoprazan’s potential entry may intensify competition with vonoprazan.

• Limited pipeline: Only a few differentiated candidates are in development.

• Underdiagnosis and misdiagnosis: Symptoms overlap with allergic and other gastrointestinal conditions.

• Subjective endpoints: Symptom-driven disease and poor alignment between endoscopic findings and symptom burden complicate trials, especially in non-erosive GERD.

• Reimbursement pressure: Payers may require PPI failure before covering branded P-CABs.

• Surgical and device alternatives: Anti-reflux surgery and implants compete for refractory patients.

Learn about new drugs, pipeline developments, and key players with DelveInsight’s expert analysis @ Gastroesophageal Reflux Disease Market Drivers and Barriers

Scope of the Gastroesophageal Reflux Disease Report

• Coverage: 7MM (US, EU4, UK, Japan)

• Companies: As listed above

• Therapies: Vonoprazan (VOQUEZNA), tegoprazan (BLI5100), ISOT-101, and others

• Assessment by Product Type: Mono, Combination, Mono/Combination

• Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Gastroesophageal Reflux Disease report today! @ Gastroesophageal Reflux Disease Companies

Table of Contents

1. Introduction

2. Executive Summary

3. Gastroesophageal Reflux Disease: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III): Tegoprazan/BLI5100 (Braintree Laboratories/Sebela Pharmaceuticals)

8. Mid Stage Products (Phase II): ISOT-101 (ISOThrive)

9. Early Stage Products (Phase I): None currently

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

19. About Us

About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and infrastructure to clients across the globe.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09650213330
Address:63, M3M 113 Market, Sector 113 NV 89107
City: Gurugram
State: IN – Indiana
Country: India
Website: https://www.delveinsight.com/consulting